Novacyt Asset Resilience Ratio
Novacyt asset resilience ratio. Novacyt (ALNOV) has an Asset Resilience Ratio of 0.02% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALNOV defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Novacyt (2008–2025)
Asset resilience ratio of Novacyt from 2008 to 2025. This chart shows how Novacyt's Asset Resilience Ratio has changed over time. Read ALNOV liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Novacyt's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Novacyt.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €9.99K | 0.02% |
| Total Liquid Assets | €9.99K | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Novacyt maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Novacyt Industry Peers by Asset Resilience Ratio
Compare Novacyt's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
T&L Co. Ltd
KQ:340570 |
Medical Devices | 26.03% |
|
Paxman AB
ST:PAX |
Medical Devices | -3.83% |
|
VIROMED MEDICAL NA O.N.
XETRA:VME |
Medical Devices | 0.03% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.48% |
|
Pulsenmore Ltd
TA:PULS |
Medical Devices | 51.61% |
|
Geratherm Medical AG
XETRA:GME |
Medical Devices | 34.89% |
Novacyt Asset Resilience Ratio by Year (2008–2025)
Novacyt asset resilience ratio by year from 2008 to 2025. The table below shows the annual Asset Resilience Ratio data for Novacyt.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.02% | €9.99K ≈ $11.68K |
€40.28 Million ≈ $47.09 Million |
-43.10pp |
| 2024-12-31 | 43.13% | €30.46 Million ≈ $35.61 Million |
€70.63 Million ≈ $82.58 Million |
+43.12pp |
| 2023-12-31 | 0.01% | €9.00K ≈ $10.52K |
€133.81 Million ≈ $156.44 Million |
-61.73pp |
| 2022-12-31 | 61.73% | €86.98 Million ≈ $101.69 Million |
€140.90 Million ≈ $164.73 Million |
+6.34pp |
| 2021-12-31 | 55.39% | €101.75 Million ≈ $118.96 Million |
€183.70 Million ≈ $214.76 Million |
+16.22pp |
| 2020-12-31 | 39.17% | €91.77 Million ≈ $107.29 Million |
€234.28 Million ≈ $273.89 Million |
+33.33pp |
| 2019-12-31 | 5.84% | €1.55 Million ≈ $1.81 Million |
€26.54 Million ≈ $31.03 Million |
+2.33pp |
| 2018-12-31 | 3.51% | €1.03 Million ≈ $1.20 Million |
€29.31 Million ≈ $34.27 Million |
+3.48pp |
| 2017-12-31 | 0.03% | €10.00K ≈ $11.69K |
€30.20 Million ≈ $35.31 Million |
+0.00pp |
| 2016-12-31 | 0.03% | €8.52K ≈ $9.97K |
€25.95 Million ≈ $30.34 Million |
-9.19pp |
| 2015-12-31 | 9.22% | €1.16 Million ≈ $1.36 Million |
€12.62 Million ≈ $14.76 Million |
+9.17pp |
| 2014-12-31 | 0.05% | €10.00K ≈ $11.69K |
€20.77 Million ≈ $24.28 Million |
-5.96pp |
| 2013-12-31 | 6.01% | €160.00K ≈ $187.06K |
€2.66 Million ≈ $3.11 Million |
-31.40pp |
| 2012-12-31 | 37.41% | €1.23 Million ≈ $1.44 Million |
€3.30 Million ≈ $3.86 Million |
+36.65pp |
| 2011-12-31 | 0.76% | €9.60K ≈ $11.22K |
€1.26 Million ≈ $1.47 Million |
+0.26pp |
| 2010-12-31 | 0.51% | €9.60K ≈ $11.22K |
€1.90 Million ≈ $2.22 Million |
-0.03pp |
| 2009-12-31 | 0.53% | €10.21K ≈ $11.94K |
€1.92 Million ≈ $2.24 Million |
-14.28pp |
| 2008-12-31 | 14.81% | €244.00K ≈ $285.26K |
€1.65 Million ≈ $1.93 Million |
-- |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more